pocketful logo light
pocketful logo light
ERIS Lifesciences Ltd logo

ERIS Lifesciences Ltd

NSE: ERIS BSE: 540596

₹1458.20

(9.13%)

Mon, 25 May 2026, 06:57 pm

mtf coin illustrationMTF 5x

Company History

2007

  • The Company was incorporated as Eris Lifescience Private Limited.
  • The name of the Company was changed to Eris Lifesciences Private Limited.
  • The Company launched the Eris division focused on cardiology and diabetes segment.

2008

  • The Company launched the Nikkos division focused on gastroenterology and orthopedics segment.

2009

  • The Company launched the Adura division focused on cardiology and diabetes segment.

2011

  • The Company launched the Montana division focused on gynecology and pediatrics segment.

2012

  • The Company launched the Inspira division focused on cardiology segment.

2013

  • The Company was awarded Competitive Strategy Leadership by Frost & Sullivan.
  • The Company was awarded Emerging Companies Excellence for scalability of business model and managing operational efficiencies by Business Today and Yes Bank.

2014

  • The Company launched the Victus division focused on anti-diabetes segment.
  • The Company set up its Assam Facility.

2015

  • The Company launched the Eris 2 division focused on pain management segment.

2016

  • The Company acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited.
  • The Company acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited.
  • The Company acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited.

2017

  • The Company was converted to a public limited company and its name was changed to Eris Lifesciences Limited.
  • The Company acquired the trademarks UNION, REUNION, and BON UNION.
  • A fresh certificate of incorporation was issued by the Registrar of Companies, Gujarat, Dadra and Nagar Haveli on February 2, 2017.

2022

  • Eris entered the dermatology therapy segment through the acquisition of Oaknet Healthcare for INR 6,500 million.

2023

  • Eris acquired the Nephrology and Dermatology Branded Formulations business units of Biocon Biologics in India.

2024

  • The Company acquired a 30% stake in Levim Lifetech Private Limited.
  • The Company acquired a 100% stake in Eris Pharmaceuticals Private Limited.